 | Up a level |
O'Donoghue, Michelle L; Rosenson, Robert S; Gencer, Baris; López, J Antonio G; Lepor, Norman E; Baum, Seth J; Stout, Elmer; Gaudet, Daniel; Knusel, Beat; Kuder, Julia F; Ran, Xinhui; Murphy, Sabina A; Wang, Huei; Wu, You; Kassahun, Helina; Sabatine, Marc S (2022). Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. New England journal of medicine NEJM, 387(20), pp. 1855-1864. Massachusetts Medical Society MMS 10.1056/NEJMoa2211023
O'Donoghue, Michelle L; G López, J Antonio; Knusel, Beat; Gencer, Baris; Wang, Huei; Wu, You; Kassahun, Helina; Sabatine, Marc S (2022). Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). American Heart Journal, 251, pp. 61-69. Elsevier 10.1016/j.ahj.2022.05.004
Nicholls, Stephen J; Nissen, Steven E; Prati, Francesco; Windecker, Stephan; Kataoka, Yu; Puri, Rishi; Hucko, Thomas; Kassahun, Helina; Liao, Jason; Somaratne, Ransi; Butters, Julie; Di Giovanni, Giuseppe; Jones, Stephen; Psaltis, Peter J (2021). Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovascular diagnosis and therapy, 11(1), pp. 120-129. AME Publishing Company 10.21037/cdt-20-684
